PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2900 Complete if Known Substitute for form 1449A/PTO **Application Number** 10/037,791 INFORMATION DISCLOSURE January 3, 2002 Filing Date STATEMENT BY APPLICANT Stanley M. Crain **First Named Inventor** 1614 Art Unit (use as many sheets as necessary) **Examiner Name** James H. Reamer Attorney Docket Number Sheet of 96700/727

		The second of th	U.S. PATE	ENT DOCUMENTS	
Examiner Initials	No.1	Document Number Number - Kind Code ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PH4	20 21	us- 4,582,835 us- 3,879,555	4/15/86 4/22/75	Lewis, et al. Pachter, et al.	
__	22 23	us- 4,935,428 us- 5,834,477	6/19/90 11/10/98	Lewis, et al. Mioduszewski	**************************************
מיצו	24	us- 4,863,928 us-	9/5/89	Atkinson, et al.	
		US- US-	angenetropia del degli provincia del provincia del degli di del degli di del degli di del degli di del degli d		
		US- US-	The state of the s		
AMERICA AND AND AND AND AND AND AND AND AND AN		US-			A 1-15 YOUR BEST TO RECEIVE WE WINDOW STORM TO THE STORM AS A STORM TO A 200 M AND A 200 M
		US-			
		US- US- US-			
		US- US-			
		US-	The state of the s	The second section of the second section of the second section is a second section of the section of the second section of the section	

	FOREIGN PATENT DOCUMENTS											
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6						
		County Case.				Ė						
		The state of the second		Transcription of the state of t								
				anno moraje i appertoro e e e e e e e e e e e e e e e e e e	1 4							
			to the second control of the second	to a compression of an entrance to the entrance of the								
		The second secon	erad to a cut- or distributed a colorescent	The state of the s	est manifestati e estre e des e e e e e e e e e e e e e e e e							
				The second secon	A REAL PROPERTY OF THE PARTY OF							
		2 Maria (10 maria 10		COLUMN TO THE PROPERTY OF THE	And the second state to the second section of the second section in the second section is the second section s							
		The second of th	AND THE HAMPHON OF THE THE CO. P. C.		DEL RESELECTE OF THE OPEN PROPERTY AND ADDRESS OF THE							
			and the second s	AND WARES								
	***************************************	Transfer that the court of the										

Examiner Date Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are recontrol number.	U.S. Patent and Trademark Of	PTO/SEWISE (10-01). Use through 10/31/2002. OMB 085/70/31 Tifice: U.S. DEPARTMENT OF COMMENTS. F If information unless it contains a valid of B	PECEIVED TOO
Substitute for form 1449B/PTO	Col	mplete if Known	16000
l •	Application Number	10/037,791	7 2900
INFORMATION DISCLOSURE	Filing Date	January 3, 2002	
STATEMENT BY APPLICANT	First Named Inventor	Stanley M. Crain	
DIAILMENT DI ALI LIOANI	Group Art Unit	1614	
(use as many sheets as necessary)	Examiner Name	James H. Reamer	\mathbf{J}
Sheet 1 of 3	Attorney Docket Number	96700/727	<i>)</i>

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
HH(1	Request for Ex Parte Reexamination of U.S. Patent No. RE 36,547.	
	2	Request for Ex Parte Reexamination of U.S. Patent No. 5,767,125.	
	3	Request for Ex Parte Reexamination of U.S. Patent No. 5,580,876.	
	4	Request for Ex Parte Reexamination of U.S. Patent No. 6,362,194	
	5	Request for Ex Parte Reexamination of U.S. Patent No. 6,096,756.	
	6	Durn and Herz, 1981, "In vivo Receptor Binding of the Opiate Partial Agonist, Buprenorphine, Correlated with its Agonistic and Antagonistic Actions," Br. J. Pharmac. 74:627-633.	
	7	Budd, 1987, "Clinical use of opioid antagonists," Balliere's Clinical Anesthesiology 1(4):993-1011.	
CONTROL OF THE MALE TO BE MALE TO THE	8	Goodman & Gilman, 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, p. 273.	
	9	Crain & Shen, 1995, Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc. Natl. Acad. Sci. U.S.A. 1995 Nov. 7;92(23):10540-10544.	
9Hsa	10	Konieczko et al. 1988, "Antagonism of morphine-induced respiratory depression with nalmefene," Br. J. Anaesth. 61:318-323.	

Examiner Signature Lames Hleann	Date Considered	9/4/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are a	U.S. Patent and Trademark Of	PTO/SB/08B (10°04) use through 10/31/2002. OMB 0651-0031 ffice: U.S. DEPARTMENT OF COMMERCE f information unless it contains a valid OMB	TEA-1000 SOUTH
Substitute for form 1449B/PTO	Co.		
	Application Number	10/037,791	
INFORMATION DISCLOSURE	Filing Date	January 3, 2002	
STATEMENT BY APPLICANT	First Named Inventor	Stanley M. Crain	
OTATEMENT BY ALL EIGHT	Group Art Unit	1614]
(use as many sheets as necessary)	Examiner Name	James H. Reamer	
Sheet 2 of 3	Attorney Docket Number	96700/727	

· · · · · · · · · · · · · · · · · · ·		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	_
Examiner Initials	Cite No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), oublisher, city and/or country where oublished	1
HK	11	Barsan et al. 1989, "Duration of Antagonistic Effects of Nalmefene and Naloxone in Opiate-induced Sedation for Emergency Department Procedures," J. Emerg. Med. 7(2); 155-161.	
1	12	Abu-Elheiga et al. 2001, "Continuous fatty acid oxidation and reduced fat storage in mice lacking Acetyl-coA carboxylase 2," Science 291:2613-16.	
	13	Goodman & Gilman (eds.), 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, "Narcotic Analgesics and Antagonists" (by J.H. Jaffe and W.R. Martin) pages 245-283.	
	14	Budd K., 1985, "The use of the opiate antagonist, naloxone, in the treatment of intractable pain." Neuropeptides. 5(4-6):419-22.	
	15	Attal et al. 1989, "Behavioural evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat." Brain Res. 494(2):276-84.	
	16	Kayser et al. 1981, "Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats." Brain Res. 226(1-2):344-8.	
	17	Kayser et al. 1984, "Further evidence for a bidirectional effect of naloxone on the pain threshold in tolerant and non-tolerant arthritic rats." Neuropeptides. 5(1-3):49-52.	
	18	Malaise & Franchimont, 1987, "Methods of clinical and biological assessment of rheumatoid arthritis." Scand. J. Rheumatol. Suppl. 65:81-4, Review.	
tha	19	Specification of US Patent No. RE 36,547.	
ren Burgar er Madern Angjy dereket			

	_			
Examiner Signature	Z	amos Meama	Date Considered	914/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial f reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

JUL 8 8 200BC 1 1 2002



		TECH CEN	TED 1000100	200					
OIPF		1 LOTT OF IT	TECHPEEN:	PER 1600/2900	ATTY, DOCKET NO.]	PATENT		
1				7000-076-999 5,767,125					
LIST OF REFERENCES CITED BY REQUESTER			ESTER	PATENT OWNER					
DEC 0 6 3	300	(Use several sheets if ne	ecessary)		Albert Einstein College of Medicii	ne of Yesh	niva Universi	ty	
X	, i	y			ISSUE DATE		GROLP		
Y C.	CHIL				June 16, 1998				
Daue	dr.			DATES TO COLOR					
	т -			S. PATENT DOCUM		F	T		
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING D IF APPROP	
HO	AA	4,582,835	4/15/86	Lewis et al.					
MM	AH	4,457,933	7/3/84	Gordon et al.					
1			FORE	IGN PATENT DOC	UMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLA	ATION
1					·			YES	NO
		OTHER R	REFERENCES (Including Author, Tit	le, Date, Pertinent Pages, Etc.)				
9188	AB				ef with naloxone. Seven	e resp	iratory d	epressi	ion
	AC	Pedersen <i>et al.</i> , 198 buprenorphine," Bri		_	nalgesic in combination 946	with h	igh dose		
	AD	Bergman <i>et al.</i> , 198 antinociceptive assa			nhances buprenorphine i yn. Ther. 291:229-37	n a too	oth pulp		
	AE	-	-	•	ing of the Opiate Partial and Antagonistic Actio	_	•	mac.	
	AF	Vaccarino <i>et al.</i> , 19 in combination with	_	-	by normal doses of opio 09	id anta	gonists a	lone a	ınd
	AG	Levine <i>et al.</i> , 1988, Invest. 82(5):1574-7		on of pentazoc	ine analgesia by low-do	se nalo	oxone," J	. Clin.	
	AI	Goodman & Gilman, 1 York, Chapter 15, p. 2		aarmacological l	Basis of Therapeutics, 5th 1	Edition,	Macmilla	an, Nev	v
	ΑJ	Specification of US	Patent No.	Re 36,547					
HM	Crain & Shen, 1995, Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10540-10544								
EXAMINER	16	mis Hlear	nn	DATE	considered 1/4/	03			
1		if reference considered, whether			h MPEP 609; Draw line through cit to owner and requester.	ation if no	ot	_	